Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat)
North America Common Warts Market is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033. The Asia Pacific is expected to grow at a CAGR.
/PRNewswire/ LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been.